Cargando…

The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report

Medication‐related osteonecrosis of the jaws (MRONJ) is a serious debilitating disease resulting from long‐term treatment with Antiresorptive drugs such as Bisphosphonates or Denosumab, which significantly affects patients' quality of life. A 43‐year‐old female patient with stage 4 breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Asfour, Maan Ahmad Rafik, Aljoujou, Abeer Ahmad, Saifo, Maher Sadik, Jabban, Haya A. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675097/
https://www.ncbi.nlm.nih.gov/pubmed/38028038
http://dx.doi.org/10.1002/ccr3.8259
_version_ 1785149781608235008
author Asfour, Maan Ahmad Rafik
Aljoujou, Abeer Ahmad
Saifo, Maher Sadik
Jabban, Haya A. L.
author_facet Asfour, Maan Ahmad Rafik
Aljoujou, Abeer Ahmad
Saifo, Maher Sadik
Jabban, Haya A. L.
author_sort Asfour, Maan Ahmad Rafik
collection PubMed
description Medication‐related osteonecrosis of the jaws (MRONJ) is a serious debilitating disease resulting from long‐term treatment with Antiresorptive drugs such as Bisphosphonates or Denosumab, which significantly affects patients' quality of life. A 43‐year‐old female patient with stage 4 breast cancer and treated with Zoledronic Acid for bone metastases was referred to the Department of Oral Medicine at the Faculty of Dentistry, Damascus University. The main complaint was pain in the right maxilla. Intraoral examination showed an exposure of necrotic bone in the right maxillary region with presence of purulent exudate. The treatment plan was discussed with the patient. Treatment included resection of all necrotic bone and application of Advanced platelet‐rich fibrin (A‐PRF) clots and membranes. Follow‐up and outcome were conducted by clinical measures to assess healing and recurrence (6‐month follow‐up). Topical treatment with A‐PRF demonstrated a reduction in pain and resulted in complete wound healing within 30 days. A‐PRF stimulates the release of growth factors and chemotaxis involved in tissue repair mechanisms. This method seemed to be effective in the treatment of MRONJ.
format Online
Article
Text
id pubmed-10675097
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106750972023-11-25 The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report Asfour, Maan Ahmad Rafik Aljoujou, Abeer Ahmad Saifo, Maher Sadik Jabban, Haya A. L. Clin Case Rep Case Report Medication‐related osteonecrosis of the jaws (MRONJ) is a serious debilitating disease resulting from long‐term treatment with Antiresorptive drugs such as Bisphosphonates or Denosumab, which significantly affects patients' quality of life. A 43‐year‐old female patient with stage 4 breast cancer and treated with Zoledronic Acid for bone metastases was referred to the Department of Oral Medicine at the Faculty of Dentistry, Damascus University. The main complaint was pain in the right maxilla. Intraoral examination showed an exposure of necrotic bone in the right maxillary region with presence of purulent exudate. The treatment plan was discussed with the patient. Treatment included resection of all necrotic bone and application of Advanced platelet‐rich fibrin (A‐PRF) clots and membranes. Follow‐up and outcome were conducted by clinical measures to assess healing and recurrence (6‐month follow‐up). Topical treatment with A‐PRF demonstrated a reduction in pain and resulted in complete wound healing within 30 days. A‐PRF stimulates the release of growth factors and chemotaxis involved in tissue repair mechanisms. This method seemed to be effective in the treatment of MRONJ. John Wiley and Sons Inc. 2023-11-25 /pmc/articles/PMC10675097/ /pubmed/38028038 http://dx.doi.org/10.1002/ccr3.8259 Text en © 2023 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Asfour, Maan Ahmad Rafik
Aljoujou, Abeer Ahmad
Saifo, Maher Sadik
Jabban, Haya A. L.
The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report
title The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report
title_full The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report
title_fullStr The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report
title_full_unstemmed The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report
title_short The use of advanced‐platelet rich fibrin (A‐PRF) in the management of medication‐related osteonecrosis of the jaw (MRONJ): A case report
title_sort use of advanced‐platelet rich fibrin (a‐prf) in the management of medication‐related osteonecrosis of the jaw (mronj): a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675097/
https://www.ncbi.nlm.nih.gov/pubmed/38028038
http://dx.doi.org/10.1002/ccr3.8259
work_keys_str_mv AT asfourmaanahmadrafik theuseofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport
AT aljoujouabeerahmad theuseofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport
AT saifomahersadik theuseofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport
AT jabbanhayaal theuseofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport
AT asfourmaanahmadrafik useofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport
AT aljoujouabeerahmad useofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport
AT saifomahersadik useofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport
AT jabbanhayaal useofadvancedplateletrichfibrinaprfinthemanagementofmedicationrelatedosteonecrosisofthejawmronjacasereport